Tag Archives: Abraxane

July, 2018

10 July
Celgene’s Tecentriq Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in Phase 3 TNBC Trial

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS). This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast …
Share

22 January
Celgene Presents Investigational Data Evaluating Abraxane Regimen for Patients with Advanced Pancreatic Cancer

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated results of secondary endpoints from the phase II international LAPACT trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) plus gemcitabine in patients with locally advanced pancreatic cancer. The results were presented today at the 2018 American …
Share

10 April
OncoMed’s Demcizumab Misses Primary Endpoint in Mid-Stage Pancreatic Cancer Trial

REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s Phase 2 YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination with Abraxane® (paclitaxel …
Share

14 December
Invisible Symptoms Impact Rheumatoid Arthritis Patients’ Lives, Hinder Diagnosis

Philadelphia, Dec. 14, 2016 – Rheumatoid Arthritis In America 2016, a national survey by Health Union of more than 3,100 individuals who identified as having rheumatoid arthritis (RA), reveals that initial symptoms are often invisible to others, with respondents experiencing more than six on average. A summary infographic is also …
Share

5 August
Momenta Halts Late-Stage Pancreatic Cancer Trial After Interim Analysis

CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced …
Share

22 January
Celgene Will Present Data from 10 Abraxane-Related Studies at ASCO GI Symposium

SUMMIT, NJ– (Jan. 22, 2016) – Celgene Corporation (NASDAQ: CELG) today announced that 10 studies highlighting combinations that include a foundation of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine are being presented during the 2016 ASCO Gastrointestinal Cancers Symposium (ASCO GI), establishing the therapy as the foundation for …
Share